Cougar Puberty Club Smart. Cheeky. Honest. Perimenopause, for real.

Scientific Reports 2026 - Estriol + Progesterone for Menopause Brain Fog (UCLA pilot)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: Scientific Reports (Nature Portfolio), 2026; DOI 10.1038/s41598-026-65603-4 · Published: September 1, 2026 · Accessed: September 8, 2026

Visit the source ↗

Claims this source supports

  • Brain fog occurs in about 62% of menopausal women; it involves domain-specific subjective symptoms plus changes on objective cognitive testing, with relative worsening in verbal memory, working memory, concentration, and processing speed, while scores remain within the normative range for age, sex, and education (Scientific Reports, Sept 1 2026).
  • There is no FDA-approved treatment for the cognitive issues of menopause; estradiol is FDA-approved for hot flashes, not for cognitive issues (Scientific Reports, Sept 1 2026).
  • Estriol is the estrogen unique to pregnancy, binding primarily to estrogen receptor beta (ER-beta), with weaker binding to ER-alpha than estradiol; it has been used safely to treat vasomotor symptoms of menopause in Europe and Asia for over 40 years (Scientific Reports, Sept 1 2026).
  • In a UCLA pilot (Voskuhl Menopause Brain Fog Assessment questionnaire), twenty menopausal women treated with estriol plus progesterone reported significant improvements from month 0 to month 12 in brain fog (r=0.899, p=0.00010), concentration (r=0.898, p=0.00037), working memory (r=0.905, p=0.00014), processing speed (r=0.903, p=0.00014), verbal memory (r=0.9, p=0.00022), and problem-solving (r=0.903, p=0.00083); paired Wilcoxon signed-rank test (Scientific Reports, Sept 1 2026).
  • Preclinical mouse data in the same research program show that midlife aging combined with complete estrogen deficiency caused hippocampal neurodegeneration, including dorsal hippocampal atrophy, astrocyte and microglia activation, and synaptic loss; the most differentially expressed astrocyte gene pathways were for glucose utilization (Scientific Reports, Sept 1 2026).
  • The study authors note the optimal type and dose of estrogen to treat cognitive issues of menopause remains unknown, and describe the pilot as early evidence in that direction (Scientific Reports, Sept 1 2026).